MedTrace Logo

Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)

NCT00304278 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-07-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer

Conditions

Interventions

DRUG

Erlotinib (Tarceva)

150 mg daily X 7 weeks

DRUG

Intra-arterial Cisplatin (PLAT)

1 dose (150 mg/sq) per week X 4 weeks

RADIATION

Radiation Therapy (RAD)

5 days per week X 7 weeks

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • OSI Pharmaceuticals

    collaborator INDUSTRY

  • Southern Illinois University

    lead OTHER

Principal Investigators

  • Krishna Rao, MD, PhD · SIU School of Medicine

  • Thomas Robbins, MD · Simmons Cancer Institute at SIU

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2015-05-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304278 on ClinicalTrials.gov